Articles producció científica> Ciències Mèdiques Bàsiques

Fucosylated N-glycans as early biomarkers of COVID-19 severity

  • Identification data

    Identifier: imarina:9322122
    Authors:
    Paton, BHerrero, PPeraire, Jdel Pino, AChafino, SMartinez-Picado, JGómez-Bertomeu, FRull, ACanela, NSuárez, M
    Abstract:
    BackgroundThe pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease. Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage. MethodsAiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19. Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression. N-glycans were released with PNGase F and labelled with Rapifluor-MS, followed by their analysis by LC-MS/MS. The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans. ResultsWe determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity. Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes. ConclusionIn this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease. Our findings show the promising potential of glycans as biomarkers of COVID-19 severity.
  • Others:

    Author, as appears in the article.: Paton, B; Herrero, P; Peraire, J; del Pino, A; Chafino, S; Martinez-Picado, J; Gómez-Bertomeu, F; Rull, A; Canela, N; Suárez, M
    Department: Ciències Mèdiques Bàsiques Bioquímica i Biotecnologia
    URV's Author/s: Gomez Bertomeu, Frederic-Francesc / HERRERO GIL, POL / Paton Jiménez, Beatrix / Peraire Forner, José Joaquin / RULL AIXA, ANNA / Suárez Recio, Manuel
    Keywords: N-glycosylation Ms Lc-ms/ms Lc-ms Fucosylation Disease Covid-19 Biomarker
    Abstract: BackgroundThe pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease. Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage. MethodsAiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19. Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression. N-glycans were released with PNGase F and labelled with Rapifluor-MS, followed by their analysis by LC-MS/MS. The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans. ResultsWe determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity. Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes. ConclusionIn this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease. Our findings show the promising potential of glycans as biomarkers of COVID-19 severity.
    Thematic Areas: Zootecnia / recursos pesqueiros Saúde coletiva Química Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Immunology and allergy Immunology Farmacia Engenharias iii Engenharias ii Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Biotecnología Biodiversidade
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: frederic-francesc.gomez@urv.cat joaquim.peraire@urv.cat beatrix.paton@estudiants.urv.cat manuel.suarez@urv.cat
    Author identifier: 0000-0002-8039-2889 0000-0001-7808-5479 0000-0003-0122-8253
    Record's date: 2024-08-03
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1204661/full
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Frontiers In Immunology. 14
    APA: Paton, B; Herrero, P; Peraire, J; del Pino, A; Chafino, S; Martinez-Picado, J; Gómez-Bertomeu, F; Rull, A; Canela, N; Suárez, M (2023). Fucosylated N-glycans as early biomarkers of COVID-19 severity. Frontiers In Immunology, 14(), -. DOI: 10.3389/fimmu.2023.1204661
    Article's DOI: 10.3389/fimmu.2023.1204661
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Immunology,Immunology and Allergy
    N-glycosylation
    Ms
    Lc-ms/ms
    Lc-ms
    Fucosylation
    Disease
    Covid-19
    Biomarker
    Zootecnia / recursos pesqueiros
    Saúde coletiva
    Química
    Odontología
    Nutrição
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Immunology and allergy
    Immunology
    Farmacia
    Engenharias iii
    Engenharias ii
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência de alimentos
    Biotecnología
    Biodiversidade
  • Documents:

  • Cerca a google

    Search to google scholar